Mocetinostat

DB11830

small molecule investigational

Deskripsi

Mocetinostat has been used in trials studying the treatment of Lymphoma, Urothelial Carcinoma, Relapsed and Refractory, Myelodysplastic Syndrome, and Metastatic Leiomyosarcoma, among others.

Struktur Molekul 2D

Berat 396.454
Wujud -

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

404 Data
Ivabradine Ivabradine may increase the QTc-prolonging activities of Mocetinostat.
Vorinostat The risk or severity of gastrointestinal bleeding and thrombocytopenia can be increased when Mocetinostat is combined with Vorinostat.
Dofetilide The risk or severity of QTc prolongation can be increased when Mocetinostat is combined with Dofetilide.
Citalopram The risk or severity of QTc prolongation can be increased when Mocetinostat is combined with Citalopram.
Anagrelide The risk or severity of QTc prolongation can be increased when Mocetinostat is combined with Anagrelide.
Disopyramide The risk or severity of QTc prolongation can be increased when Mocetinostat is combined with Disopyramide.
Clemastine The risk or severity of QTc prolongation can be increased when Mocetinostat is combined with Clemastine.
Ibutilide The risk or severity of QTc prolongation can be increased when Mocetinostat is combined with Ibutilide.
Valproic acid The risk or severity of QTc prolongation can be increased when Mocetinostat is combined with Valproic acid.
Terfenadine The risk or severity of QTc prolongation can be increased when Mocetinostat is combined with Terfenadine.
Grepafloxacin The risk or severity of QTc prolongation can be increased when Mocetinostat is combined with Grepafloxacin.
Quinine The risk or severity of QTc prolongation can be increased when Mocetinostat is combined with Quinine.
Sotalol The risk or severity of QTc prolongation can be increased when Mocetinostat is combined with Sotalol.
Erlotinib The risk or severity of QTc prolongation can be increased when Mocetinostat is combined with Erlotinib.
Toremifene The risk or severity of QTc prolongation can be increased when Mocetinostat is combined with Toremifene.
Cisapride The risk or severity of QTc prolongation can be increased when Mocetinostat is combined with Cisapride.
Imatinib The risk or severity of QTc prolongation can be increased when Mocetinostat is combined with Imatinib.
Astemizole The risk or severity of QTc prolongation can be increased when Mocetinostat is combined with Astemizole.
Thioridazine The risk or severity of QTc prolongation can be increased when Mocetinostat is combined with Thioridazine.
Trovafloxacin The risk or severity of QTc prolongation can be increased when Mocetinostat is combined with Trovafloxacin.
Mifepristone The risk or severity of QTc prolongation can be increased when Mocetinostat is combined with Mifepristone.
Cocaine The risk or severity of methemoglobinemia can be increased when Mocetinostat is combined with Cocaine.
Quinidine The risk or severity of QTc prolongation can be increased when Mocetinostat is combined with Quinidine.
Procainamide The risk or severity of QTc prolongation can be increased when Mocetinostat is combined with Procainamide.
Pimozide The risk or severity of QTc prolongation can be increased when Mocetinostat is combined with Pimozide.
Amiodarone The risk or severity of QTc prolongation can be increased when Mocetinostat is combined with Amiodarone.
Arsenic trioxide The risk or severity of QTc prolongation can be increased when Mocetinostat is combined with Arsenic trioxide.
Escitalopram The risk or severity of QTc prolongation can be increased when Mocetinostat is combined with Escitalopram.
Domperidone The risk or severity of QTc prolongation can be increased when Mocetinostat is combined with Domperidone.
Sparfloxacin The risk or severity of QTc prolongation can be increased when Mocetinostat is combined with Sparfloxacin.
Halofantrine The risk or severity of QTc prolongation can be increased when Mocetinostat is combined with Halofantrine.
Bepridil The risk or severity of QTc prolongation can be increased when Mocetinostat is combined with Bepridil.
Paliperidone The risk or severity of QTc prolongation can be increased when Mocetinostat is combined with Paliperidone.
Lithium cation The risk or severity of QTc prolongation can be increased when Mocetinostat is combined with Lithium cation.
Temafloxacin The risk or severity of QTc prolongation can be increased when Mocetinostat is combined with Temafloxacin.
Zuclopenthixol The risk or severity of QTc prolongation can be increased when Mocetinostat is combined with Zuclopenthixol.
Tetrabenazine The risk or severity of QTc prolongation can be increased when Mocetinostat is combined with Tetrabenazine.
Dronedarone The risk or severity of QTc prolongation can be increased when Mocetinostat is combined with Dronedarone.
Nilotinib The risk or severity of QTc prolongation can be increased when Mocetinostat is combined with Nilotinib.
Iloperidone The risk or severity of QTc prolongation can be increased when Mocetinostat is combined with Iloperidone.
Vandetanib The risk or severity of QTc prolongation can be increased when Mocetinostat is combined with Vandetanib.
Romidepsin The risk or severity of QTc prolongation can be increased when Mocetinostat is combined with Romidepsin.
Asenapine The risk or severity of QTc prolongation can be increased when Mocetinostat is combined with Asenapine.
Artemether The risk or severity of QTc prolongation can be increased when Mocetinostat is combined with Artemether.
Lumefantrine The risk or severity of QTc prolongation can be increased when Mocetinostat is combined with Lumefantrine.
Vemurafenib The risk or severity of QTc prolongation can be increased when Mocetinostat is combined with Vemurafenib.
Eliglustat The risk or severity of QTc prolongation can be increased when Mocetinostat is combined with Eliglustat.
Ribociclib The risk or severity of QTc prolongation can be increased when Ribociclib is combined with Mocetinostat.
Glasdegib The risk or severity of QTc prolongation can be increased when Mocetinostat is combined with Glasdegib.
Deutetrabenazine The risk or severity of QTc prolongation can be increased when Mocetinostat is combined with Deutetrabenazine.
Macimorelin The risk or severity of QTc prolongation can be increased when Mocetinostat is combined with Macimorelin.
Terodiline The risk or severity of QTc prolongation can be increased when Mocetinostat is combined with Terodiline.
Leuprolide The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Mocetinostat.
Goserelin The risk or severity of QTc prolongation can be increased when Goserelin is combined with Mocetinostat.
Erythromycin The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Mocetinostat.
Azithromycin The risk or severity of QTc prolongation can be increased when Azithromycin is combined with Mocetinostat.
Moxifloxacin The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Mocetinostat.
Ranolazine The risk or severity of QTc prolongation can be increased when Ranolazine is combined with Mocetinostat.
Sulfisoxazole The risk or severity of QTc prolongation can be increased when Sulfisoxazole is combined with Mocetinostat.
Amitriptyline The risk or severity of QTc prolongation can be increased when Amitriptyline is combined with Mocetinostat.
Methadone The risk or severity of QTc prolongation can be increased when Methadone is combined with Mocetinostat.
Diltiazem The risk or severity of QTc prolongation can be increased when Diltiazem is combined with Mocetinostat.
Clozapine The risk or severity of QTc prolongation can be increased when Mocetinostat is combined with Clozapine.
Sulpiride The risk or severity of QTc prolongation can be increased when Sulpiride is combined with Mocetinostat.
Nimodipine The risk or severity of QTc prolongation can be increased when Nimodipine is combined with Mocetinostat.
Promazine The risk or severity of QTc prolongation can be increased when Promazine is combined with Mocetinostat.
Prochlorperazine The risk or severity of QTc prolongation can be increased when Prochlorperazine is combined with Mocetinostat.
Droperidol The risk or severity of QTc prolongation can be increased when Droperidol is combined with Mocetinostat.
Imipramine The risk or severity of QTc prolongation can be increased when Imipramine is combined with Mocetinostat.
Chlorpromazine The risk or severity of QTc prolongation can be increased when Chlorpromazine is combined with Mocetinostat.
Oxaliplatin The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Mocetinostat.
Ciprofloxacin The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Mocetinostat.
Fluorouracil The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Mocetinostat.
Perflutren The risk or severity of QTc prolongation can be increased when Perflutren is combined with Mocetinostat.
Cinnarizine The risk or severity of QTc prolongation can be increased when Cinnarizine is combined with Mocetinostat.
Atropine The risk or severity of QTc prolongation can be increased when Atropine is combined with Mocetinostat.
Chloroquine The risk or severity of QTc prolongation can be increased when Chloroquine is combined with Mocetinostat.
Efavirenz The risk or severity of QTc prolongation can be increased when Efavirenz is combined with Mocetinostat.
Adenosine The risk or severity of QTc prolongation can be increased when Adenosine is combined with Mocetinostat.
Pentamidine The risk or severity of QTc prolongation can be increased when Pentamidine is combined with Mocetinostat.
Gadobenic acid The risk or severity of QTc prolongation can be increased when Gadobenic acid is combined with Mocetinostat.
Carbinoxamine The risk or severity of QTc prolongation can be increased when Carbinoxamine is combined with Mocetinostat.
Dolasetron The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Mocetinostat.
Roxithromycin The risk or severity of QTc prolongation can be increased when Roxithromycin is combined with Mocetinostat.
Nalidixic acid The risk or severity of QTc prolongation can be increased when Nalidixic acid is combined with Mocetinostat.
Cinoxacin The risk or severity of QTc prolongation can be increased when Cinoxacin is combined with Mocetinostat.
Loperamide The risk or severity of QTc prolongation can be increased when Loperamide is combined with Mocetinostat.
Granisetron The risk or severity of QTc prolongation can be increased when Granisetron is combined with Mocetinostat.
Ondansetron The risk or severity of QTc prolongation can be increased when Ondansetron is combined with Mocetinostat.
Levosimendan The risk or severity of QTc prolongation can be increased when Levosimendan is combined with Mocetinostat.
Mesoridazine The risk or severity of QTc prolongation can be increased when Mesoridazine is combined with Mocetinostat.
Desloratadine The risk or severity of QTc prolongation can be increased when Desloratadine is combined with Mocetinostat.
Telithromycin The risk or severity of QTc prolongation can be increased when Telithromycin is combined with Mocetinostat.
Lomefloxacin The risk or severity of QTc prolongation can be increased when Lomefloxacin is combined with Mocetinostat.
Dimenhydrinate The risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Mocetinostat.
Primaquine The risk or severity of QTc prolongation can be increased when Primaquine is combined with Mocetinostat.
Papaverine The risk or severity of QTc prolongation can be increased when Papaverine is combined with Mocetinostat.
Chlorpheniramine The risk or severity of QTc prolongation can be increased when Chlorpheniramine is combined with Mocetinostat.
Nifedipine The risk or severity of QTc prolongation can be increased when Nifedipine is combined with Mocetinostat.
Levofloxacin The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Mocetinostat.

Target Protein

Histone deacetylase 1 HDAC1
Histone deacetylase 3 HDAC3
Histone deacetylase 2 HDAC2

Referensi & Sumber

Artikel (PubMed)
  • PMID: 17621879
    Kell J: Drug evaluation: MGCD-0103, a histone deacetylase inhibitor for the treatment of cancer. Curr Opin Investig Drugs. 2007 Jun;8(6):485-92.
  • PMID: 17455259
    Beckers T, Burkhardt C, Wieland H, Gimmnich P, Ciossek T, Maier T, Sanders K: Distinct pharmacological properties of second generation HDAC inhibitors with the benzamide or hydroxamate head group. Int J Cancer. 2007 Sep 1;121(5):1138-48.
  • PMID: 17868033
    Khan N, Jeffers M, Kumar S, Hackett C, Boldog F, Khramtsov N, Qian X, Mills E, Berghs SC, Carey N, Finn PW, Collins LS, Tumber A, Ritchie JW, Jensen PB, Lichenstein HS, Sehested M: Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem J. 2008 Jan 15;409(2):581-9.

Contoh Produk & Brand

Produk: 0 • International brands: 0
Belum ada data produk/brand untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field produk/brand.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul